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Abstract: The aetiology and pathogenesis of bacterial vaginosis (BV) is unclear but  
it appears to be associated with factors that disrupt the normal acidity of the vagina thus 
altering the equilibrium between the normal vaginal microbiota. BV has serious implications 
for female morbidity, including reports of pelvic inflammatory disease, adverse pregnancy 
outcomes, increased susceptibility to sexually transmitted infections and infertility.  
This paper reviewed new available information regarding possible factors contributing to 
the establishment of the BV vaginal biofilm, examined the proposed role of anaerobic 
microbial species recently detected by new culture-independent methods and discusses 
developments related to the effects of BV on human pregnancy. The literature search 
included Pubmed (NLM), LISTA (EBSCO), and Web of Science. Because of the complexity 
and diversity of population groups, diagnosis and methodology used, no meta-analysis was 
performed. Several anaerobic microbial species previously missed in the laboratory 
diagnosis of BV have been revealed while taking cognisance of newly proposed theories of 
infection, thereby improving our understanding and knowledge of the complex aetiology 
and pathogenesis of BV and its perceived role in adverse pregnancy outcomes. 
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1. Introduction 
Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality world-wide, yet,  
the underlying causes remain largely unknown, with increased incidence reported due to intrauterine 
infections [1,2]. Bacterial vaginosis (BV) is a common reproductive tract infection amongst women of 
reproductive age [3] and has been implicated as a risk factor for adverse pregnancy outcomes such as 
preterm birth, recurrent abortions, post-abortal sepsis, early miscarriages and still births [2,4–7]. 
Infections leading to preterm birth and other complications of pregnancy may extend beyond delivery 
and create serious and sometimes life-threatening consequences for the neonate [8]. However, many 
infections are subclinical [9] and so our knowledge of the role played by BV in PTB remains limited 
and inconclusive.  
Previously considered to be an infection initiated by the overgrowth of Gardnerella vaginalis  
with a concomitant loss of H2O2-producing lactobacilli, new evidence points to BV as being  
a polymicrobial condition, involving synergistic mechanisms between vaginal colonisers,  
many of which are anaerobic bacteria. Confirmation of this theory is found in the resistance to 
metronidazole of many BV infections, and the finding that the volatile fatty acids responsible for the 
“whiff test” are products of the metabolic activity of a host of anaerobes other than G. vaginalis [10]. 
Although not classified as a sexually transmitted infection (STI) per se, the risk for sexual transmission 
of certain BV-associated bacteria has been reported to increase in lesbian and heterosexual women with 
multiple sexual partners [11–13].  
2. Methodology  
Citation databases included Sciencedirect, PubMed, LISTA (EBSCO), and Web of Science,  
using the terms “bacterial vaginosis”, “vaginitis”, “vaginal discharge”, “aetiology of vaginosis”, 
“anaerobes in vaginosis”, “preterm birth and vaginosis”, “preterm delivery and asymptomatic infections”, 
“pathogenesis of bacterial vaginosis”, “virulence factors of vaginal anaerobes”, “diagnosis of vaginosis” 
and “vaginal microbial ecology”. All titles and available abstracts were screened and where relevant, 
full texts retrieved. In addition, reference lists of retrieved papers were examined for similar papers 
which could be relevant. More than 700 papers were retrieved in the initial search but only 161 papers 
pertaining to specific BV-associated anaerobes in pregnancy and published between the years 2000 
and 2014 were included, except for a few specific earlier papers on which diagnostic methods  
were based. Data regarding bacteria detected, method of detection, type of study (case/control  
or cohort) virulence mechanisms and implication in adverse pregnancy outcomes were collected and 
summarised. While not claiming to be all-inclusive, an attempt was made to include the viewpoints 
and research outcomes which contributed new and pertinent data. Overt differences in diagnosis,  
proposed aetiology, sampling, detection methods, population groups and periods of gestation 
complicated a meta-analysis.  
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3. Results and Discussion 
3.1. Transition from the Lactobacillus-Associated to the BV-Associated Vaginal Biofilm 
The vaginal ecosystem is established over a number of years. The dynamic environment of the 
vagina is influenced by factors such as hormonal fluctuations, menstruation, douching, hygiene, 
pregnancy, breastfeeding and sexual practices [14–27]. Skin commensals and microbiota normally 
inhabiting the bowel are the original colonisers of the young, healthy female vagina. Aerobic lactobacilli 
persist in the vagina for weeks after birth while the vaginal pH remains acidic. The pH of the vagina 
converts to neutral during early childhood, remaining so until puberty. A plethora of different microbial 
species co-exist in this vaginal ecosystem, 70%–90% of which are lactobacilli. During puberty and 
menarche, dramatic hormonal and physical changes occur in the vaginal environment favouring the 
colonisation of lactobacilli [26]. Although identified in both BV-positive and BV-negative women,  
H2O producing lactobacilli numbers are reported to be significantly increased in BV-negative females [28]. 
Their population dominance is considered to be beneficial in maintaining the health of the female, 
through their production of hydroxyl radicals, lactic acid, bacteriocins, hydrogen peroxide and 
probiotics [5]. After menopause, or when the vaginal lactobacilli are depressed or removed,  
hydrogen peroxide is no longer produced and the pH of the environment increases, thus facilitating  
the establishment of BV-associated microbial communities in the vaginal biofilm [23,29].  
However, not all healthy females have vaginal microbiota dominated by lactobacilli [5],  
and other lactic acid producers such as Atopobium vaginae, Leptotrichia and Megasphaera have also 
been suggested to assist in maintaining the acidity of the vagina, [30,31]. With BV considered a  
non-specific (predominantly anaerobic) polymicrobial infection and the identities of many of  
the vaginal microflora remaining elusive [32], determining the health of the vaginal ecosystem appears  
to be subjective.  
Two species of lactobacilli have frequently been found to colonise the healthy vagina, namely, 
Lactobacillus gasseri and Lactobacillus crispatus both members of the Lactobacillus acidophilus 
complex [33,34]. While L. crispatus and L. jensenii have a better ability to adhere to vaginal cells [35], 
in vitro studies have reported that acid and hydrogen peroxide production by L. acidophilus and  
L. casei are able to inhibit the growth of BV-associated microbes such as Gardnerella vaginalis, 
Mobiluncus, Bacteroides and species of anaerobic cocci, while decreased production of bacteriocins 
and hydrogen-peroxide by lactobacilli enhances the growth of G. vaginalis, Prevotella bivia, 
Mobiluncus, Peptococcus species and Peptostreptococcus anaerobius by the production of ammonia, 
acetic, succinic acids and amino acids respectively [36].  
Lactobacillus iners has been recommended as a marker of the imbalance of the vaginal microflora 
leading to BV [33,37,38] and its presence correlated with colonisation of other BV-associated bacteria 
such as Megasphaera, Leptotrichia and Eggerthella [39]. Thus the significance of the relative ratio of 
Lactobacillus iners, Atopobium vaginae and other anaerobes in BV provides substantial information 
for its diagnosis [38]. L. gassei and L. crispatus, have been associated with health, while a negative 
correlation has been reported between L. gasseri and L. iners; L. gasseri and Atopobium,  
Prevotella and G. vaginalis all of which are associated with BV [37,39–41]. L. iners is dominant after 
treatment for BV, and has been reported together with L. crispatus in women without BV [34] 
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suggesting that L. iners may be an opportunistic pathogen whose prevalence and pathogenic potential 
is enhanced by L. gassei, an assumed later coloniser than L. crispatus.  
Several mechanisms have been proposed for the establishment of the BV biofilm, namely, stress, 
sexual practices, microbial synergism (one organism inducing the ideal growing environment for another) 
or antagonism (inhibition or killing of one organism by another). Because of the polymicrobial nature 
of infection, growing resistance to metronidazole and other antimicrobial treatments have been 
reported [42]. The outcome of any infection is usually determined by the initial response of the host to 
invasion by an infective agent, followed by chemotaxis (the migration of polymorphonuclear 
neutrophils (PMNs) towards the locus of infection). This initial response to the recognition of 
chemotactic factors results in phagocytosis. In an effort to fully understand BV, clinicians made a 
distinction between vaginitis and vaginosis by defining bacterial vaginitis as an infection of the vagina 
associated with inflammation of the vulva, while vaginosis was defined as the degradation of the 
normal flora of the vagina in the absence of an associated inflammatory response [43]. The inhibition 
of PMN chemotaxis by virulence factors expressed by certain of the BV-associated organisms,  
may explain the absence of inflammation.  
In order to be implicated in the aetiology of BV, a specific bacterium should demonstrate an 
increase in BV and be reduced or eliminated in the healthy vagina. BV has been attributed to an 
imbalance of the normal vaginal microbiota with many of the anaerobic bacteria detected in BV 
showing great pathogenic potential either individually or as a consortium. Symbiotic relationships 
appear to play an important role in the pathogenesis of BV, thereby implicating several species in its 
aetiology. They are examined below in the light of their effect on host defences, provision of essential 
nutrients for growth and survival, alteration of the environment and expression of virulence factors.  
3.2. Anaerobes Implicated in the Aetiology of BV 
Gardnerella vaginalis has for a long time been seen as one of the most important candidate bacteria 
in BV [27,44–46], with its numbers being inversely proportionate to lactobacilli in health and  
disease [17,18]. However, recognising only Gardnerella vaginalis as the overt pathogen in BV would 
be inaccurate, especially as G. vaginalis has shown a high sensitivity (100%) but low specificity (49%) 
for BV by also being detected in the absence of BV [14,16,28,47]. Synergy between G. vaginalis and 
Atopobium vaginae has been proposed as they are often detected together in BV [32,48–52] and only 
rarely has A. vaginae been detected in the absence of G. vaginalis [53] or in health [54,55].  
A. vaginae was first implicated in BV in 2004, since then several studies have emerged associating this 
anaerobe with >80% of BV cases [54,56–61]. Furthermore, a specific consortium including  
A. vaginae, and Leptotrichia was found to enhance the pathogenic potential of Megasphaera  
in BV [62], suggesting a role for A. vaginae in the aetiology of BV. Megasphaera has a symbiotic 
existence in the vaginal biofilm [63] and appears to be sexually transmitted, being strongly associated 
with women who have sex with women and with heterosexual women reporting an increased number  
of sexual partners [15,25].  
Taxonomically unidentified bacteria designated BVAB (bacterial vaginosis associated bacteria) 
have morphologic features distinctly different from Atopobium, Mobiluncus, or Gardnerella and have 
been observed microscopically in patients with BV, attached to vaginal epithelial cells typical of the 
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clue cells that characterise BV [47,64]. BVAB have been reported in HIV-positive women with BV [65] 
and are considered to be acquired from external reservoirs such as the anus [66]. Also associated with 
BV infection in HIV-positive women are M. hominis and a combination of Bacteroides, Prevotella, 
Leptotrichia, Atopobium and Gardnerella [49,67–72] known to attract CD4 cells to the mucosa,  
with a concomitant reduction in lactobacilli [67]. Among the Gram-positive anaerobic cocci known to 
colonise the vagina are Peptococcus, Peptostreptococcus, Peptoniphilus and Anaerococcus.  
However, Gram-positive anaerobic cocci have not received the attention they deserve in studies of  
the vaginal biofilm despite their perceived pathogenic potential and their production of metabolic end 
products which favour the growth of other BV-associated microbes such as Megasphaera [63]. 
Furthermore, an association between endometritis and BV-associated anaerobic Gram-positive cocci 
has been established [73], confirming their role in reproductive morbidity. 
Leptotrichia amnionii and Sneathia sanguinegens (previously Leptotrichia sanguinegens) are 
known colonisers of the oral cavity and like other oral anaerobes implicated in the aetiology of 
periodontal disease such as Tannerella forsythia, Treponema denticola, Prevotella intermedia, 
Aggrigatibacter actinomycetemcomitans (Aa) and Porphyromonas gingivalis, have also been 
associated with BV [74]. Their presence in the vagina may be due to translocation during oral-gential 
sexual practices since they are rarely found in sexually unexposed women [15]. Known to co-colonise 
with G. vaginalis and other anaerobes such as Prevotella in cases of BV [49,58], L. amnionii and  
S. sanguinegens although significantly increased in women with cervical cancer, show no correlation 
with human papillomavirus which has been implicated in the aetiology of cervical cancer and their 
detection in healthy women suggests that their pathogenicity may be opportunistic [75].  
3.3. Diagnosis of Bacterial Vaginosis  
Diagnosis of BV includes clinical examination and microscopy [76,77], using Amsel criteria and 
Nugent scoring [78,79]. BV is characterised by a discharge (often white or yellow) with a fishy odour 
following the addition of 10% potassium hydroxide to the vaginal fluid, vaginal pH > 4.5 and the 
microscopic scoring of bacterial morphotypes along with the presence of “clue cells”, vaginal epithelial 
cells with boarders coated with bacteria [80]. It may also be asymptomatic [9,26] which explains why 
it is often misdiagnosed [30]. It may be differentiated from aerobic vaginitis, which is characterised by 
the absence of succinate, increased sialidase activity and a host response resulting in the increased 
production of cytokines such as interleukin-1, -6 and -8 [43,81].  
Laboratory-based diagnostic methods for BV include culture and anaerobic metabolic activity 
analysis such as the assessment of the production of short-chain volatile and non-volatile fatty acids as 
end products of anaerobic metabolism, and the production of specific enzymes, [82–86]. Detection of 
fatty acids in vaginal fluid [87–89] can differentiate between health (major lactic acid) and BV  
(major succinic and acetic acids) as well as monitor the effects of treatment for BV. Culture-based and 
molecular approaches have identified several anaerobic species in BV [18,28,39,40,48,53,90,91]  
with molecular methods having overcome many of the problems associated with culture and revealing 
species not previously reported. This has indeed awakened our awareness of the complexity of  
the microbial biofilm of BV (Table 1) as well as the risk and treatment of ascending subclinical 
infections [92]. Of the many bacteria implicated in the aetiology of BV, Leptotrichia amnionii and 
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Eggerthella species are the only two species found to correlate with all of the Amsel criteria used for 
the diagnosis of BV [34] and in cases where no discharge is present, improved grading of bacterial 
morphotypes in a wet mount or Gram stain of vaginal fluid has been recommended as an alternative to 
Amsel criteria for the diagnosis of BV [93].  
Table 1. Anaerobic microbial consortia most frequently associated with bacterial vaginosis 
and preterm birth. 
Reference 
Gram-negative Anaerobes Gram-positive Anaerobes 
La Ss Por Pr Di Av Gv Mob Li BVAB Egg Meg Anaer Ps Pep
[9] x   x x x x    x     
[10] x x    x     x x    
[15]      x x   x  x    
[18]    x  x x         
[24] x x  x  x x    x     
[25] x x    x x   x  x   x 
[34] x x    x x   x x     
[50]   x x  x   x   x x x x 
[55]       x x x  x x  x x 
[58] x x x  x x x  x  x x x x x 
[64] x x    x    x      
[94] x   x x x x x x  x x  x x 
[95] x x  x  x x    x x    
[96]    x   x x        
[97] x   x        x    
[98] x x    x    x      
[99]  x    x x         
[100] x     x      x    
Notes: Av = Atopobium vaginae; Mob = Mobiluncus; Li = Lactobacillus iners; BVAB = BV-associated 
bacteria (unidentified); Egg = Eggerthella; Meg = Megasphaera; Anaer = Anaerococcus  
(previously Peptostreptococcus); Pep = Peptoniphilus (previously Peptostreptococ). 
Since the focus of this paper is directed at the microbes implicated in the aetiology and 
pathogenesis of BV and the role it may play in PTB, it will not elaborate on the details of these 
different diagnostic approaches, the strengths and weaknesses of which have previously  
been summarised [101]. 
3.4. The Pathogenic Potential of BV-associated Anaerobes 
3.4.1. Co-Aggregation and Attachment 
G. vaginalis has been reported to possess innate pathogenic potential [44] with two genomically 
different forms described: one being a commensal form slightly adhesive to epithelial cells, and the other,  
a pathogenic form found to be strongly adhesive to epithelial cells [33]. Because adherence is a vitally 
important virulence factor in the pathogenesis of BV, the ability of G. vaginalis to adhere to vaginal 
epithelial cells may well pave the way for other microbes such as Peptoniphilus and A. vaginae  
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to become established in the BV-associated vaginal biofilm by co-aggregating with G. vaginalis  
in order to establish infection [44,102].  
Other species such as Fusobacterium which also do not adhere well to vaginal epithelial cells [44], 
are able to facilitate co-aggregation between species such as Prevotella [103] and Bifidobacterium [104] 
in polymicrobial infections [105,106] by acting as a bridge between early and late colonisers in  
biofilm formation [107–109] and by supporting the growth of obligate anaerobes such as 
Porphyromonas, [110,111] in aerated and carbon dioxide depleted environments [110–112].  
By adhering to other vaginal microbes [113], F. nucleatum is able to mask the surface components that 
are recognized by H2O2-producing lactobacilli and prevent detection by antagonistic microflora thus 
allowing for its integration into the developing vaginal microbial community associated with BV [114]. 
Bifidobacterium and Ureaplasma urealyticum have the ability to attach to erythrocytes and other 
eucaryotic cells, [115] and have therefore been reported to be independently associated with BV [9]. 
However, Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium breves, 
Bifidobacterium bifidum and Bifidobacterium catenulatum have been detected perianally only and not 
in the vagina [116], possibly due to weaker adherence mechanisms. While unable to co-aggregate 
directly with Actinomyces naeslundi or with Veillonella parvula, Bifidobacterium is known to attach to 
biofilms of A. naeslundii and V. parvula, in the presence of F. nucleatum [104] and may further 
contribute to the formation of the vaginal biofilm by producing amino acids which provide energy 
sources to other anaerobic bacteria such as Eggerthella lenta (previously Eubacterium lenta).  
3.4.2. Production of Volatile and Non-Volatile Fatty Acids 
Volatile fatty acids such as isovaleric or caproic acid are produced by species of Gram-positive 
cocci which induce alterations of the shape, composition and growth of eukaryotic cells [88] and may 
thus threaten pregnancy. Non-volatile fatty acids produced by vaginal anaerobes have been shown to 
inhibit chemotaxis and other PMN functions [88,117]. Other fatty acids produced by vaginal anaerobes 
include formic acid produced by Atopobium and Eggerthella, propionic acid produced by 
Propionibacterium, lactic acid produced by Bifidobacterium, Atopobium, Actinomyces,  
Collinsella aerofaciens (previously Eubacterium aerofaciens), Lactobacillus, Leptotrichia amnionii 
and Sneathia sanguinegens, butyric acid produced by Eubacterium, Slackia, Gram-positive cocci and 
acetic and succinic acids produced by anaerobic Gram-positive cocci, Mobiluncus, Prevotella, 
Atopobium, Bifidobacterium, Eggerthella, Actinomyces [118]. The production of malic acid and 
trimethylamine by Mobiluncus have been associated with vaginal irritation and the vaginal odour 
associated with BV, while Fusobacterium nucleatum is known to produce large amounts of ammonia, 
butyrate and hydrogen sulfide and thus, along with supporting the growth of other anaerobes,  
could also be contributing to the malodour associated with BV [119,120].  
The production of amines such as putrescine and cadaverine by anaerobic bacteria, resulting in an 
increase in pH and favouring the growth of other anaerobes implicated in BV is an example of 
bacterial synergy in the establishment of the vaginosis biofilm.  
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3.4.3. Enzyme and Lysine Production 
Mucin degrading enzymes produced by BV-associated bacteria deplete protective host mucous 
barriers [121] and facilitate adhesion to and colonisation of the underlying epithelium [122].  
The production of collagenase and fibrinolysins by Prevotella bivia, Prevotella disiens and Leptorichia 
are reported to play a role in pathogenesis by degrading mucosal protective factors and detachment of 
vaginal epithelial cells [82] thereby contributing to the production of a vaginal discharge.  
Cytolysins are produced by L. iners [123] and G. vaginalis, causing cell death by activating the protein 
kinase pathway in human epithelial cells [44,124]. The production of IgA antibodies to vaginolysin 
(cytolysin produced by G. vaginalis) as a result of the mucosal immune response, further supports the 
role of vaginolysin in the pathogenesis of BV [125]. G. vaginalis also produces haemolysin, liberating 
nutrients for the feeding of other anaerobic bacteria. It has been suggested that U. urealyticum is the 
most virulent of the mollicutes [115], expressing haemolytic activity and secretion of enzymes such as 
elastase, IgA protease (reducing mucosal immunity), phospholipase C, [126], and urease which 
hydrolyses urea to cytotoxic ammonia. Vaginal sloughing is facilitated by the production of sialidase, 
prolidase [117,121] and putrescine by G. vaginalis, Mobilincus [122] Megasphaera, [62],  
Bactroides fragilis [122] and Prevotella bivia [82,117]. Proteolytic enzymes produced by many 
anaerobic species [44] damage oviduct mucosal surfaces, render the cilia unable to beat, and could 
possibly lead to infertility [127,128]. 
3.5. Bacterial Vaginosis and Its Threat to Pregnancy 
Vaginal mucosal cells and their glycoproteins are major components of the barrier which protects 
against infection. Cervical mucous protects the upper reproductive tract from microbial invasion. 
Among the antibacterial factors contained in mucous are lactoferrin, lysozyme and secretory IgA.  
The amount and viscosity of mucosal flow is determined by the cervical mucins and thus reduced 
viscosity of the mucous allows for better infiltration of pathogens into the reproductive tract [122]. 
Evidence is mounting that ascending subclinical intrauterine infections in the gravid female may 
threaten pregnancy due to a host of different proinflammatory endogenous vaginal colonisers.  
By promoting colonisation of the upper reproductive tract, mucin degrading enzymes produced by  
BV-associated bacteria sometimes cause chorioamnionitis and other adverse pregnancy outcomes. 
Chemotactic cytokines are produced by several cell types, including injured tissues, and by acting on 
leucocytes, are involved in stimulating inflammatory mediators [26]. High vaginal bacterial loads may 
cause an increase in cytokine levels [129] particularly when G. vaginalis, F. nucleatum, staphylococci 
and streptococci are present [92]. G. vaginalis and A. vaginae frequently occur together in PTB [130,131], 
with A. vaginae also being detected in endometritis [132] a condition which may occur not only 
amongst non-pregnant women (in pelvic inflammatory disease), but could also occur after child birth 
or as a result of Casaerian delivery. Other BV-associated microbes associated with PTB include 
Mobiluncus, Mycoplasma [133] along with Bacteroides ureolyticus [134,135] and Fusobacterium [136].  
L. amnionii and S. sanguinegens have been reported in pregnancy [137], and ascending infections 
involving the uterus, foetal membranes and fallopian tubes [138]. Being increasingly reported from 
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obstetrics cases [85] they are associated with spontaneous abortion [138], septic abortion [139],  
PTB [86,140], peripartum fever [141] postpartum infection [138,141], and bacteraemia [142].  
Although considered to be an indicator organism for BV [143,144], the role of Megasphaera in 
preterm birth remains speculative. M. hominis appears to increase the prevalence of U. urealyticum,  
C. trachomatis [145], BV and preterm delivery [146]. Together, M. hominis and U. urealyticum have 
been reported in cervicitis, pelvic inflammatory disease and obstetrical pathologies including premature 
delivery, premature rupture of membranes, chorio-amniotitis and pregnancy loss [9,145,147,148], 
while U. parvum has been associated with preterm birth and late spontaneous abortion [149].  
The role of M. genitalium in both BV and pregnancy outcomes is less well defined since its presence 
appears to be dependent on other vaginal colonisers. The production of sialidase and other proteolytic 
enzymes capable of damaging host tissues and threatening pregnancy may implicate many of the 
anaerobic vaginal microflora in adverse pregnancy outcomes [121,150].  
4. Summary and Conclusions 
Anaerobes dominate the microbiota of the human skin and mucous membranes and are thus 
commonly implicated in bacterial endogenous infections. Their identification and treatment are 
complicated by their inability to grow in routine culture thus resulting in their presence being missed 
or overlooked. The use of 16S rRNA gene sequence-based analyses have frequently been used for the 
study of the vaginal microbiota, thus revealing the presence of many anaerobic species not previously 
detected by culture [57,58]. Our knowledge of the diversity of species associated with BV has thus 
increased as detection methods have improved [44,94]. 
The polymicrobial ecosystem of the vagina complicates the determination of the microbial 
aetiology of BV. Using culture-independent techniques, attempts have been made to differentiate the 
diversity of vaginal microbiota in BV-positive and BV-negative women [62,95,151], but there is no 
consensus regarding the microbial communities which bring about the change from a commensal 
microflora to an opportunistic microflora causing BV. Many of the studies reported, differ in patient 
selection, population groups, sampling techniques, diagnostic methods and laboratory detection methods 
with some studies (particularly molecular studies) selecting for the presence of specific species only 
and others (cultural studies) limited by the lack of nutrients required for the growth of fastidious 
species, thus leading to either over or under-representation of the prevalence of particular species.  
The HIV-exposed foetus is at risk for PTB [152] thus the viricidal effect of H2O2-producing 
lactobacilli and the stimulation of growth factors by BV-associated bacteria have a direct impact on 
foetal and neonatal morbidity and mortality due to maternal HIV status [153]. However, conclusive 
evidence that treatment of BV reduces PTB is lacking thus BV is not considered by many as being a 
specific marker for PTB and focus is thus directed to the development of other biomarkers for adverse 
pregnancy outcomes. It has been suggested that aerobic vaginitis is a more serious threat for adverse 
pregnancy outcomes than BV [43] since it appears to be more damaging to the healthy vaginal 
environment than BV [81] and the increased cytokine production is thought to increase the risk of 
preterm delivery, chorioamnionitis and funisitis of the foetus [154].  
Whether or not screening for BV, prevents PTB remains to be debated [155–157].  
While some recommend that treatment of BV reduces the risk of PTB, others report an increase in 
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PTB following treatment for BV [158]. Meanwhile, BVAB3 an anerobe prevalent in BV, was found to 
decrease the risk for PTB [133], a finding which may explain why come cases of BV may be involved 
in PTB and others not. Inconsistencies in clinical and laboratory detection methods used for the 
monitoring of treatment have a direct impact on success rates [76,83,155,159] thus complicating a 
comparison between the presence/absence of BV in PTB and full-term birth (FTB) [156].  
Because different bacteria have different associations with Amsel diagnostic criteria, this may explain 
discrepancies often reported between Amsel criteria and microscopy [34]. Amsel clinical criteria 
provide no information on the vaginal microflora and while microscopy may provide information 
pertaining to the morphology of the vaginal bacteria, it provides no confirmation of the species present. 
Although strongly associated with BV, many bacteria have not been taxonomically identified [47,58], 
further adding to the complexity of the matter.  
With some species associated with both health and disease, one needs to examine their pathogenic 
potential within specific microbial consortia, taking into account the inherent differences within and 
among different ethnic groups [160], sexual and hygiene practices, and host susceptibility [23].  
It has been proposed that more information regarding the aetiology of BV may be attained by 
aggregating the microflora into higher taxonomic groups instead of considering the vaginal microflora 
at genus or species level [151] and that if the occurrence of BV is reduced and a healthy vaginal 
biofilm maintained, new cases of HIV infections may be considerably prevented [161] as will adverse 
pregnancy outcomes. Studies demonstrating the ability of specific bacteria to overcome immunity and 
alter the environment (be it synergistically or antagonistically) in favour of their survival, will greatly 
improve our understanding of the complexity of BV [39,47] and the microbial stimuli of inflammatory 
reactions which may initiate the cascade of events leading to preterm delivery. It is therefore 
imperative that a better understanding of the vaginal microbiome with a more explicit differentiation 
between health and disease microbiota be established, taking into account other risk factors which may 
modify their colonisation and pathogenic potential.  
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